The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03383-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Therapy, 2025. Verfasst von Salvatore Tafuto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sarcomas and Rare Tumors, Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, Naples, Italy. Hauptthemen laut MEDLINE: Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Farma s.p.a..
Abstract (Originalsprache)
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) comprise a heterogeneous group of clinically diverse tumors; their management is based on clinical characteristics. International guidelines recommend standard-dose somatostatin analogues (SSAs) as first-line treatment for advanced, low-grade G1 and "low" G2 NETs. No standard-of-care treatment is determined for "high" G2 and G3 NETs. Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE was authorized to treat well-differentiated (G1 and G2) unresectable or metastatic, somatostatin receptor (SSTR)-positive GEP-NETs, in progression after SSA. Recently published NETTER-2 is the first randomized clinical trial to demonstrate the efficacy and safety of [177Lu]Lu-DOTA-TATE as first-line treatment in patients with newly diagnosed, advanced "high" G2 and G3 GEP-NETs. In February 2024, 13 scientific board members discussed RLT guidelines and treatment perspectives in patients with GEP-NETs based on NETTER-2 outcomes. In their opinion, NETTER-2 will impact first-line treatment choice in patients with G2 SSTR-positive GEP-NETs. RLT as first-line treatment could reduce tumor burden rather than maintain stable disease, except in patients who are highly symptomatic where chemotherapy should be considered. In patients with G3 SSTR-positive GEP-NETs, NETTER-2 strongly supports RLT as potential first-line treatment. RLT could also have a significant role in a perioperative setting for those cases with borderline resectable disease or advanced oligometastatic disease. The results of NETTER-2 confirm that therapy selection should be guided by symptoms, syndrome, and functional expression of SSTR within the tumor site(s) rather than GEP-NET histology and grading. Thus, the scientific board agreed that RLT should always be considered in SSTR-positive GEP-NETs. Graphical Abstract available for this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Sarcomas and Rare Tumors, Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, Naples, Italy.
- Department of Nuclear Medicine and Therapy With Radionuclides, Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, ENETS Center of Excellence, Naples, Italy.
- Department of Surgical-Medical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy. francesco.panzuto@unirom…
- Department of Experimental Clinical Medicine, University of Florence, Florence, Italy.
- Clinical Oncology Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
- Department of Medical and Surgical Sciences, Alma Mater Studiorum, Università degli Studi di Bologna, Bologna, Italy.
Förderung
- Novartis Farma s.p.a.
Zitieren
APA
Tafuto, S., Lastoria, S., Panzuto, F., Antonuzzo, L., Campana, D., Cingarlini, S., Cives, M., Ferone, D., Filice, A., Giuffrida, D., Maccauro, M., Partelli, S., & Fazio, N. (2025). The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion. Advances in Therapy. https://doi.org/10.1007/s12325-025-03383-5
Vancouver
Tafuto S, Lastoria S, Panzuto F, Antonuzzo L, Campana D, Cingarlini S, et al. The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion. Advances in Therapy. 2025. doi:10.1007/s12325-025-03383-5
BibTeX
@article{Tafuto2025,
author = {Tafuto, Salvatore and Lastoria, Secondo and Panzuto, Francesco and Antonuzzo, Lorenzo and Campana, Davide and Cingarlini, Sara and Cives, Mauro and Ferone, Diego and Filice, Angelina and Giuffrida, Dario and Maccauro, Marco and Partelli, Stefano and Fazio, Nicola},
title = {The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03383-5}
}
EUVIMED